Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential
Author Information
Author(s): Gilardini Montani Maria Saveria, Benedetti Rossella, Cirone Mara
Primary Institution: Department of Experimental Medicine, Sapienza University of Rome, Italy
Hypothesis
EZH2 plays a critical role in cancer progression and immune escape, making it a potential target for therapeutic intervention.
Conclusion
Targeting EZH2 may enhance cancer treatment by reversing its oncogenic effects and improving immune responses.
Supporting Evidence
- EZH2 is often dysregulated in cancer, contributing to carcinogenesis and immune escape.
- Targeting EZH2 may enhance the effectiveness of cancer immunotherapy.
- Inhibitors of EZH2 have been developed and some are FDA-approved for cancer treatment.
Takeaway
EZH2 is a protein that helps cancer grow, and scientists are looking for ways to stop it to help treat cancer better.
Methodology
This review summarizes the mechanisms by which EZH2 regulates tumor suppressor genes and oncogenic molecules, as well as strategies for its inhibition.
Limitations
The review does not present new experimental data but synthesizes existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website